Botulinum Toxin Type A for Chronic Migraine

@article{Ashkenazi2010BotulinumTT,
  title={Botulinum Toxin Type A for Chronic Migraine},
  author={Avi Ashkenazi},
  journal={Current Neurology and Neuroscience Reports},
  year={2010},
  volume={10},
  pages={140-146}
}
  • A. Ashkenazi
  • Published 24 February 2010
  • Medicine
  • Current Neurology and Neuroscience Reports
Chronic migraine (CM) is the leading cause of chronic daily headache, a common and debilitating headache syndrome. The management of CM patients is challenging, with only limited benefit from available oral preventive medications. Botulinum neurotoxin (BoNT) has been used extensively to treat disorders associated with increased muscle tone. More recent scientific data support an analgesic effect of the toxin. The pharmacokinetic and pharmacodynamic profiles of BoNT make it an appealing… 
Botulinum Therapy for Chronic Migraine
TLDR
BoNT-A is a safe drug with no systemic reactions in clinical trials for headache, and recent randomized controlled trials evaluating the efficacy of botulinum toxin A have confirmed its efficacy for CM prophylaxis.
Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience
TLDR
A group of patients suffering from chronic migraine with medication overuse was treated with onabotulinum toxin A (Botox) to verify its efficacy for chronic migraine, and the efficacy was confirmed when used at the dosage of 155 UI according to the PREEMPT protocol.
Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience
TLDR
A group of patients suffering from chronic migraine with medication overuse was treated with onabotulinum toxin A (Botox) to verify its efficacy for chronic migraine, and results confirmed the efficacy when used at the dosage of 155 UI according to the PREEMPT protocol.
Refractory Chronic Migraine Therapy with Botulinum Toxin A
Once diagnosis of a migraine is made (including imaging studies to rule out secondary headaches, criterion E of ICHD 1.1 or 1.2), no further diagnostic workup is needed before initiating a treatment
Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse
TLDR
A group of patients suffering from CM with medication overuse was treated with BoNT-A to verify its efficacy for CM and assess its clinical applicability, and results confirmed the efficacy when used at the dosage of 155 UI, according with the PREEMPT study protocol.
OnabotulinumtoxinA for the Treatment of Headache
TLDR
The efficacy of onabotulinumtoxinA for some headaches, its long duration of action, and its favorable adverse effect profile make it a viable treatment option for the appropriate headache patients.
Botulinum Neurotoxin for Pain Management: Insights from Animal Models
TLDR
This review highlights recent findings on the effects of BoNTs in animal pain models, with emphasis for its possible use in modulation and alleviation of chronic pain.
Botulinum Toxin Type A Therapy in Migraine: Preclinical and Clinical Trials
TLDR
The evidence that BTX-A decreases NTG-induced CGRP-LI and SP-LI levels in trigeminovascular system suggests that BTx-A attenuates migraine by suppression of neuropeptide release.
Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
TLDR
Assessment of the efficacy in daily clinical practice of BT-A injections in refractory CM patients, regardless of medication overuse without any standardized withdrawal protocol and without stopping the ongoing prophylaxis treatment, found that onabotulinum toxin A treatment is effective in improving clinical outcome and quality of life.
Botulinum Toxin Type A—A Modulator of Spinal Neuron–Glia Interactions under Neuropathic Pain Conditions
TLDR
Whether and how Botulinum neurotoxin A affects the spinal neuron–glia interaction and reduces the development of neuropathy is discussed.
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Botulinum toxin and other new approaches to migraine therapy.
TLDR
Clinical trials support the efficacy of BTX type A (and possibly also type B) in the treatment of migraine and the high tolerability of the AT1 receptor blocker candesartan warrants further studies to assess its role in migraine prevention.
Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse
TLDR
This study undertakes to examine the effects of Botulinum Toxin Type A in the absence of medication overuse in patients with chronic migraine.
Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A
TLDR
The finding that exploding headache was impervious to extracranial BTX‐A injections is consistent with the prevailing view that migraine pain is mediated by intracranial innervation.
Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study
TLDR
BOTOX was found to be a safe and effective therapy for both acute and prophylactic treatment of migraine headaches and the complete potential for the neuroinhibitory effects of botulinum toxin is explored.
Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase
TLDR
In PREEMPT 2, BoNTA was effective as prophylaxis of headache in adults with CM and significantly reduced headache-related disability and improved functioning and overall quality of life.
Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study
Objective.—To assess the efficacy and safety of botulinum toxin type A (BoNT‐A; BOTOX®, Allergan, Inc., Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH)
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
TLDR
BoNTA was safe and well tolerated, and the 225 U and 150 U groups experienced a greater decrease in headache frequency than the placebo group at day 240.
Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled Trial
TLDR
The safety and efficacy of botulinum toxin type A (BoNT‐A; BOTOX®, Allergan, Inc.) for the prophylactic treatment of chronic daily headache is evaluated.
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
TLDR
It is demonstrated that local peripheral injection of BoNT‐A significantly reduces formalin‐induced nociceptive behaviors with the absence of obvious muscle weakness.
Botulinum toxin for diabetic neuropathic pain
TLDR
This pilot study found that botulinum toxin type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality.
...
1
2
3
4
...